Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG-Reference-Cited by-同舟云学术

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG

Published:2006-04 Issue:4 Volume:17 Page:563-570
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Schadendorf D.,Ugurel S.,Schuler-Thurner B.,Nestle F.O.,Enk A.,Bröcker E.-B.,Grabbe S.,Rittgen W.,Edler L.,Sucker A.,Zimpfer-Rechner C.,Berger T.,Kamarashev J.,Burg G.,Jonuleit H.,Tüttenberg A.,Becker J.C.,Keikavoussi P.,Kämpgen E.,Schuler G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/17/4/563/685418/mdj138.pdf

Reference26 articles.

1. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system;Balch;J Clin Oncol,2001

2. Palliative treatment of disseminated malignant melanoma: a systemic review of 41 randomised clinical trials;Eigentler;Lancet Oncol,2003

3. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma;Scheibenbogen;J Immunother,2000

4. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma;Rosenberg;Nat Med,1998

5. Cancer immunotherapy: moving beyond current vaccines;Rosenberg;Nat Med,2004

Cited by 394 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis;Human Vaccines & Immunotherapeutics;2024-03-27

2. Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective;IET Nanobiotechnology;2024-02-24

3. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial;Nature Communications;2024-02-23

4. Mechanisms and measures to modulate T cell trafficking for amplified and tolerogenic immunity;Nano Today;2024-02

5. Combined Osteopontin Blockade and Type 2 Classical Dendritic Cell Vaccination as Effective Synergetic Therapy for Conjunctival Melanoma;The Journal of Immunology;2023-12-15